VeriSim acquires drug discovery company Molomics Biotech

By The Science Advisory Board staff writers

May 12, 2022 -- VeriSim Life has acquired Molomics Biotech, a privately held drug discovery company that uses artificial intelligence (AI) technology to design more efficacious and safer therapeutics for an undisclosed amount.

The Barcelona-based firm incorporates AI with human collective intelligence to determine novel chemical structures with high therapeutic activity on diseases such as Parkinson's and levodopa-induced dyskinesia. The technology will integrate into VeriSim's virtual drug development engine, BioiSim, to further improve the success rates for the discovery, development, and approval of new drugs, the firms said.

Copyright © 2022
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here